Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

133 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Effect of HIPEC according to HRD/BRCAwt genomic profile in stage III ovarian cancer: Results from the phase III OVHIPEC trial.
Koole SN, Schouten PC, Hauke J, Kluin RJC, Nederlof P, Richters LK, Krebsbach G, Sikorska K, Alkemade M, Opdam M, Schagen van Leeuwen JH, Schreuder HWR, Hermans RHM, de Hingh IHJT, Mom CH, Arts HJG, van Ham M, van Dam P, Vuylsteke P, Sanders J, Horlings HM, van de Vijver KK, Hahnen E, van Driel WJ, Schmutzler R, Sonke GS, Linn SC. Koole SN, et al. Among authors: van de vijver kk, van dam p, van ham m, van driel wj. Int J Cancer. 2022 Oct 15;151(8):1394-1404. doi: 10.1002/ijc.34124. Epub 2022 Jun 4. Int J Cancer. 2022. PMID: 35583992 Free article. Clinical Trial.
Health-related quality of life after interval cytoreductive surgery with or without hyperthermic intraperitoneal chemotherapy (HIPEC) in patients with stage III ovarian cancer.
Koole SN, Kieffer JM, K Sikorska, Schagen van Leeuwen JH, Schreuder HWR, Hermans RH, de Hingh IH, van der Velden J, Arts HJ, van Ham MAPC, Aalbers AG, Verwaal VJ, Van de Vijver KK, Sonke GS, van Driel WJ, Aaronson NK. Koole SN, et al. Among authors: van ham mapc, van de vijver kk, van der velden j, van driel wj. Eur J Surg Oncol. 2021 Jan;47(1):101-107. doi: 10.1016/j.ejso.2019.05.006. Epub 2019 May 13. Eur J Surg Oncol. 2021. PMID: 31128948 Clinical Trial.
Primary cytoreductive surgery with or without hyperthermic intraperitoneal chemotherapy (HIPEC) for FIGO stage III epithelial ovarian cancer: OVHIPEC-2, a phase III randomized clinical trial.
Koole S, van Stein R, Sikorska K, Barton D, Perrin L, Brennan D, Zivanovic O, Mosgaard BJ, Fagotti A, Colombo PE, Sonke G, Driel WJV; OVHIPEC-2 Steering Committee and the Dutch OVHIPEC group. Koole S, et al. Int J Gynecol Cancer. 2020 Jun;30(6):888-892. doi: 10.1136/ijgc-2020-001231. Epub 2020 Mar 23. Int J Gynecol Cancer. 2020. PMID: 32205449 Free PMC article.
No influence of sarcopenia on survival of ovarian cancer patients in a prospective validation study.
Ubachs J, Koole SN, Lahaye M, Fabris C, Bruijs L, Schagen van Leeuwen J, Schreuder HWR, Hermans RH, de Hingh IH, van der Velden J, Arts HJ, van Ham M, van Dam P, Vuylsteke P, Bastings J, Kruitwagen RFPM, Lambrechts S, Olde Damink SWM, Rensen SS, Van Gorp T, Sonke GS, van Driel WJ. Ubachs J, et al. Among authors: van gorp t, van dam p, van ham m, van der velden j, van driel wj. Gynecol Oncol. 2020 Dec;159(3):706-711. doi: 10.1016/j.ygyno.2020.09.042. Epub 2020 Oct 2. Gynecol Oncol. 2020. PMID: 33019981
Central radiology assessment of the randomized phase III open-label OVHIPEC-1 trial in ovarian cancer.
Koole SN, Bruijs L, Fabris C, Sikorska K, Engbersen M, Schagen van Leeuwen JH, Schreuder HWR, Hermans RH, van der Velden J, Arts HJG, van Ham M, Van Dam P, Vuylsteke P, Lahaye M, Sonke G, Driel WV. Koole SN, et al. Among authors: van dam p, van ham m, van der velden j. Int J Gynecol Cancer. 2020 Dec;30(12):1928-1934. doi: 10.1136/ijgc-2020-001825. Epub 2020 Oct 12. Int J Gynecol Cancer. 2020. PMID: 33046576
Corrigendum to: Postoperative outcomes of primary and interval cytoreductive surgery for advanced ovarian cancer registered in the Dutch Gynecological Oncology Audit (DGOA) [Gynecologic Oncology Volume 162, Issue 2, August 2021, Pages 331-338].
Tewarie NMSB, van Driel WJ, van Ham M, Wouters MW, Kruitwagen R; participants of the Dutch Gynecological Oncology Collaborator Group. Tewarie NMSB, et al. Among authors: van ham m, van driel wj. Gynecol Oncol. 2021 Dec;163(3):615. doi: 10.1016/j.ygyno.2021.09.019. Epub 2021 Oct 1. Gynecol Oncol. 2021. PMID: 34607710 Free article. No abstract available.
Guideline adherence in ovarian cancer for surgical staging in the Netherlands.
Baldewpersad Tewarie NMS, van Ham M, Wouters M, Kruitwagen R, van Driel W; participants of the Dutch Gynecological Oncology Collaborator Group; participants of the Dutch Gynecological Oncology Collaborator Group. Baldewpersad Tewarie NMS, et al. Among authors: van driel w, van ham m. Int J Gynecol Cancer. 2022 Dec 5;32(12):1592-1598. doi: 10.1136/ijgc-2022-003666. Int J Gynecol Cancer. 2022. PMID: 36270772
Cytoreductive surgery with or without hyperthermic intraperitoneal chemotherapy in patients with advanced ovarian cancer (OVHIPEC-1): final survival analysis of a randomised, controlled, phase 3 trial.
Aronson SL, Lopez-Yurda M, Koole SN, Schagen van Leeuwen JH, Schreuder HWR, Hermans RHM, de Hingh IHJT, van Gent MDJM, Arts HJG, van Ham MAPC, van Dam PA, Vuylsteke P, Aalbers AGJ, Verwaal VJ, Van de Vijver KK, Aaronson NK, Sonke GS, van Driel WJ. Aronson SL, et al. Among authors: van ham mapc. Lancet Oncol. 2023 Oct;24(10):1109-1118. doi: 10.1016/S1470-2045(23)00396-0. Epub 2023 Sep 11. Lancet Oncol. 2023. PMID: 37708912 Clinical Trial.
Phenotype-guided targeted therapy based on functional signal transduction pathway activity in recurrent ovarian cancer patients: The STAPOVER study protocol.
van der Ploeg P, Hendrikse CS, Thijs AM, Westgeest HM, Smedts HP, Vos MC, Jalving M, Lok CA, Boere IA, van Ham MA, Ottevanger PB, Westermann AM, Mom CH, Lalisang RI, Lambrechts S, Bekkers RL, Piek JM. van der Ploeg P, et al. Among authors: van ham ma. Heliyon. 2023 Dec 1;10(1):e23170. doi: 10.1016/j.heliyon.2023.e23170. eCollection 2024 Jan 15. Heliyon. 2023. PMID: 38187310 Free PMC article.
133 results